Onward Medical N.V. (ONWD.BR)
EUR 4.23
(0.95%)
EUR 4.23
(0.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 532 Thousand EUR | -75.23% |
| 2022 | 2.14 Million EUR | 53.54% |
| 2021 | 1.39 Million EUR | 74.88% |
| 2020 | 800 Thousand EUR | 44.4% |
| 2019 | 554 Thousand EUR | 16.88% |
| 2018 | 474 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 104 Thousand EUR | 152.53% |
| 2024 Q2 | 104 Thousand EUR | 0.0% |
| 2023 Q1 | 464 Thousand EUR | -21.69% |
| 2023 FY | 532 Thousand EUR | -75.23% |
| 2023 Q4 | -198 Thousand EUR | 7.48% |
| 2023 Q3 | -214 Thousand EUR | -146.12% |
| 2023 Q2 | 464 Thousand EUR | 0.0% |
| 2022 Q1 | 481.5 Thousand EUR | 18.45% |
| 2022 Q3 | 592.5 Thousand EUR | 23.05% |
| 2022 Q4 | 592.5 Thousand EUR | 0.0% |
| 2022 Q2 | 481.5 Thousand EUR | 0.0% |
| 2022 FY | 2.14 Million EUR | 53.54% |
| 2021 Q1 | 293 Thousand EUR | -0.51% |
| 2021 FY | 1.39 Million EUR | 74.88% |
| 2021 Q4 | 406.5 Thousand EUR | 0.0% |
| 2021 Q3 | 406.5 Thousand EUR | 38.74% |
| 2021 Q2 | 293 Thousand EUR | 0.0% |
| 2020 Q2 | 105.5 Thousand EUR | 0.0% |
| 2020 Q3 | 294.5 Thousand EUR | 179.15% |
| 2020 Q1 | 105.5 Thousand EUR | 0.0% |
| 2020 FY | 800 Thousand EUR | 44.4% |
| 2020 Q4 | 294.5 Thousand EUR | 0.0% |
| 2019 FY | 554 Thousand EUR | 16.88% |
| 2018 FY | 474 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nicox S.A. | 257 Thousand EUR | -107.004% |
| European Medical Solutions | 40.56 Million EUR | 98.688% |
| FERMENTALG | 4.05 Million EUR | 86.887% |
| argenx SE | 1.13 Billion EUR | 99.953% |
| BioSenic S.A. | 543 Thousand EUR | 2.026% |
| Celyad Oncology SA | 102 Thousand EUR | -421.569% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 74.509% |
| Oxurion NV | 263 Thousand EUR | -102.281% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 59.879% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.99% |